This study is being done to find out if the experimental drug INCB024360 is safe and has helpful effects when given to women with a certain type of ovarian cancer. Women who have elevated CA-125 (a marker in the blood used to track the disease) and no evidence of disease ("biochemical recurrent only") after achieving complete remission with first-line chemotherapy will be asked to take part. This study will measure how long women who take INCB024360 survive without disease recurrence after study treatment, compared to those that take a hormonal therapy called tamoxifen. About 110 women with biochemical recurrent only ovarian cancer will be participating at approximately 35 study centers.
Sharon Stockman, 319-356-2015
A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects With Heart Failure. The purpose of this trial is to assess whether MYDICAR can reduce the frequency and/or delay heart failure related hospitalizations in persons with advanced heart failure when added to their maximal and optimized therapy.
Please refer to www.clinicaltrials.gov identifier NCT01643330
for more information.
A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure (CUPID-2b)
Cardiomyopathy Treatment Program
Cynthia Larew, RN BSN
Research Study to Investigate the Effects of a Common Anti-inflammatory Drug on Blood Vessel and Heart FunctionHealthy, non-smoking adults age 50-79 years and age18-39 years are invited for a University of Iowa (UI) study of the effects of anti-inflammatory therapy on blood vessel and heart function. Female participants 50+ years must be postmenopausal for at least one year.Subjects must be willing to fast for 8 hours prior to testing.
Participants will visit UI's Institute for Clinical and Translational Science Clinical Research Unit 9 times over a 6-7 week period.Participants will have a variety of cardiovascular measurements and blood samples taken at baseline and then again after taking an aspirin-like drug called Salsalate or a placebo for 4 weeks.Participants will be compensated for their time.Please contact Veronica Howsare at (319) 356-0578 for more information.
Veronica Howsare: (319) 356-0578
Men and women with non-GERD non-cardiac chest pain are invited to participate in a University of Iowa research study investigating the effects of an investigational medication as a potential treatment for subjects with chest pain not related to heart disease.
The study involves 4 visits with each visit ranging from 30 minutes to 2 hours. The study tests are provided at no cost. Compensation is provided.
Jessica Valestin at 319-384-9756 or firstname.lastname@example.org
Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure (ZS-01-210)
Recombinant human Neuregulin-1 (rhNRG-1, also called ) is a 61 amino acid peptide that acts directly on damaged heart muscle cells to restore their structure and function. This randomized, parallel, placebo-controlled, double-blind, multi-center study will assess the safety and efficacy of rhNRG-1 also known as Neucardin as a treatment for stable chronic heart failure.
Copyright © 2013 The University of Iowa. All Rights Reserved.